Project BioShield Success Depends on Ability to Guarantee Consistent, Long-Term Financing, Markets and Indemnity for Biodefense Vaccine Developers, Testifies AVANT Immunotherapeutics CEO.
Business Wire › April 04, 2003
Linked as:
Extract
Project BioShield Success Depends on Ability to Guarantee Consistent, Long-Term Financing, Markets and Indemnity for Biodefense Vaccine Developers, Testifies AVANT Immunotherapeutics CEO.
Business Editors/Health/Medical Writers
BIOWIRE2K WASHINGTON--(BUSINESS WIRE)--April 4, 2003 Biotechnology companies are well suited to address the modest commercial opportunities offered by creating safer, more effective and less costly vaccines for biodefense. However, the ultimate effectiveness of Project BioShield -- aimed at supporting such product development - depends on its ability to provide consistent and well-coordinated, long-term financing and sufficient, ensured markets, as well as a d...See the full content of this document
Sponsored links
